- Home
- MYGN vs IGD Comparison
MYGN vs IGD Comparison
Compare MYGN & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- IGD
- Stock Information
- Founded
- MYGN 1991
- IGD N/A
- Country
- MYGN United States
- IGD United States
- Employees
- MYGN N/A
- IGD N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IGD Trusts Except Educational Religious and Charitable
- Sector
- MYGN Health Care
- IGD Finance
- Exchange
- MYGN Nasdaq
- IGD Nasdaq
- Market Cap
- MYGN 423.1M
- IGD 459.8M
- IPO Year
- MYGN 1995
- IGD N/A
- Fundamental
- Price
- MYGN $6.02
- IGD $5.88
- Analyst Decision
- MYGN Hold
- IGD
- Analyst Count
- MYGN 13
- IGD 0
- Target Price
- MYGN $13.50
- IGD N/A
- AVG Volume (30 Days)
- MYGN 2.4M
- IGD 215.3K
- Earning Date
- MYGN 08-05-2025
- IGD 01-01-0001
- Dividend Yield
- MYGN N/A
- IGD 9.15%
- EPS Growth
- MYGN N/A
- IGD N/A
- EPS
- MYGN N/A
- IGD N/A
- Revenue
- MYGN $832,900,000.00
- IGD N/A
- Revenue This Year
- MYGN N/A
- IGD N/A
- Revenue Next Year
- MYGN $6.64
- IGD N/A
- P/E Ratio
- MYGN N/A
- IGD N/A
- Revenue Growth
- MYGN 3.83
- IGD N/A
- 52 Week Low
- MYGN $3.76
- IGD $4.60
- 52 Week High
- MYGN $29.30
- IGD $5.26
- Technical
- Relative Strength Index (RSI)
- MYGN 62.34
- IGD 60.29
- Support Level
- MYGN $5.23
- IGD $5.81
- Resistance Level
- MYGN $6.07
- IGD $5.88
- Average True Range (ATR)
- MYGN 0.39
- IGD 0.05
- MACD
- MYGN 0.05
- IGD 0.01
- Stochastic Oscillator
- MYGN 81.27
- IGD 96.75
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.